Efficacy and Safety of Degarelix in Taiwanese Patients with Prostate Cancer Requiring Androgen Deprivation Therapy: An Open-label, Multicenter Phase III Study

Background: Pivotal phase III data have shown the efficacy and safety of degarelix (240 mg starting dose/80 mg maintenance dose [240/80 mg]) in North American and European patients with prostate cancer (PCa). This open-label, multicenter, single-arm trial has evaluated the efficacy and safety of degarelix in Taiwanese patients with PCa